华润医药(03320.HK)与纳米及先进材料研发院推动阿兹海默病创新治疗

阿斯达克财经
14 Jan

华润医药(03320.HK) 与纳米及先进材料研发院(NAMI)今天(14日)签署合作框架协议,双方将携手推进“Palbociclib在阿兹海默病治疗中的纳米传递优化”项目,并由香港大学支援药效研究,致力应对阿兹海默病这一全球医疗领域的挑战。

全球目前有逾5,000万名患者罹患阿兹海默病,随着全球老龄化加剧,预计患者数量将持续攀升,长远为医疗系统带来沉重负担。通过结合NAMI的新型药物输送系统和华润医药在制药领域的知识,改善药物的纳米传递,开发出更高药物疗效而且更具成本效益的治疗方案。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-14 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10